FGFR3 and cancer: Du et al. (2021) recently reported a bivalent degrader DGY-09-192, which coupled pan-FGFR inhibitor BGJ-398 to a CRL2VHL E3 ligase (Figure 15). Surprisingly, DGY-09-192 preferentially induced FGFR1 and FGFR2 degradation while largely sparing FGFR3 and FGFR4. Despite multiple concerns regarding cellular permeability, the feasibility of scalable synthesis, and so on (Goracci et al., 2020; Liu et al., 2020), these pioneering studies have demonstrated that the PROTAC approach has a great potential to expand the arsenal against a variety of FGFRs-altered cancers.